19:19 , Jul 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer; colorectal cancer; pancreatic cancer In vitro and cell culture studies identified a hydrazone-based inhibitor of RRM1 that could help treat breast, colorectal and pancreatic cancers. In silico screening of a small molecule...
07:00 , Mar 21, 2016 |  BioCentury  |  Emerging Company Profile

Targeting toxicity

Novonco Therapeutics Inc. is developing a pipeline of targeted cancer therapies that were designed at City of Hope and University of California Irvine to be less toxic than either first-generation inhibitors, or parent molecules. Its...
07:00 , Jul 23, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Ribonucleotide reductase M1 (RRM1; R1); ribonucleotide reductase M2 (RRM2; R2)

Cardiovascular disease INDICATION: Heart failure Pig studies suggest RRM1 and RRM2 gene therapy could help treat heart failure. In a minipig model of heart failure, intracoronary infusion of an adeno-associated virus (AAV) serotype 6 (AAV6)...
08:00 , Feb 19, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Ribonucleotide reductase M1 (RRM1; R1); ribonucleotide reductase M2 (RRM2; R2)

Cardiovascular disease INDICATION: Heart failure Studies in human samples suggest 2-deoxy ATP (dATP) could help treat heart failure. In de-membranated multicellular preparations of ventricular wall tissue from patients with end-stage heart failure, treatment with dATP...
08:00 , Feb 19, 2015 |  BC Innovations  |  Targets & Mechanisms

Ace of hearts

Less than two years after coming out of stealth mode, University of Washington spinout Beat BioTherapeutics Corp. has shown preclinical proof of concept for its heart failure gene therapy designed to provide dATP as an...
14:51 , Feb 13, 2015 |  BC Innovations  |  Targets & Mechanisms

Ace of hearts

Less than two years after coming out of stealth mode, University of Washington spinout Beat BioTherapeutics Corp. has shown preclinical proof of concept for its heart failure gene therapy designed to provide dATP as an...
08:00 , Jan 21, 2008 |  BC Week In Review  |  Company News

Genzyme, Moffitt Cancer Center deal

Genzyme Corp. (NASDAQ:GENZ), Cambridge, Mass.   Moffitt Cancer Center , Tampa, Fla.   Business: Pharmacogenetics   The center granted Genzyme exclusive, worldwide rights to develop and commercialize diagnostics that use two protein biomarkers to predict...
01:23 , Feb 24, 2007 |  BC Extra  |  Clinical News

Researchers report NSCLC survival determinants

Researchers from the H. Lee Moffitt Cancer Center published in The New England Journal of Medicine that the proteins RRM1 and ERCC1 are determinants of survival after surgical treatment of early-stage, non-small cell lung cancer...
08:00 , Mar 13, 2006 |  BC Week In Review  |  Clinical News

Lorus preclinical data

Researchers published in the International Journal of Oncology that in various mice models of solid tumors, GTI-2501 showed potent antitumor activity against a variety of tumors. GTI-2501 also prevented metastasis of human melanoma cells to...
07:00 , May 2, 2005 |  BC Week In Review  |  Clinical News

PGN1164: Development discontinued

PGN discontinued the development of Phase I compound PGN1164 due to variable pharmacokinetics in healthy volunteers. PGN1164 was part of PGN's R1 program, which is developing a series of serotonin 5-HT2B receptor antagonists to treat...